CONSISTENCY OF FRIEDEWALD, MARTIN/HOPKINS AND SAMSON FORMULAS FOR LDL-C CALCULATION IN HIGH AND VERY HIGH CARDIOVASCULAR RISK PATIENTS

被引：0
|
作者：
Basaran, O. [1 ]
Dogan, V. [1 ]
Celik, O. [1 ]
Cil, C. [2 ]
Ozlek, B. [2 ]
Ozlek, E. [2 ]
Ozdemir, I. H. [3 ]
Rencuzogullari, I. [4 ]
Karadeniz, F. [5 ]
Tekinalp, M. [6 ]
Askin, L. [7 ]
Demirelli, S. [5 ]
Gencer, E. [8 ]
Biteker, M. [1 ]
Kayikcioglu, M. [9 ]
机构：
[1] Mugla Sitki Kocman Univ, Cardiol, Mugla, Turkey
[2] Mugla Sitki Kocman Univ Educ & Res Hosp, Cardiol, Mugla, Turkey
[3] Nizip State Hosp, Cardiol, Gaziantep, Turkey
[4] Kars Univ, Cardiol, Kars, Turkey
[5] Erzurum Educ & Res Hosp, Cardiol, Erzurum, Turkey
[6] Necip Fazil State Hosp, Cardiol, Kahramanmaras, Turkey
[7] Adiyaman Univ, Cardiol, Adiyaman, Turkey
[8] Kilis State Hosp, Cardiol, Kilis, Turkey
[9] Ege Univ, Cardiol, Sch Med, Izmir, Turkey
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP231
引用
收藏
页码：E160 / E160
页数：1
相关论文
共 50 条
  • [31] Comparison of measured and calculated LDL-cholesterol by Friedewald and Martin-Hopkins equation in samples with high triglyceride concentration
    Radman, A.
    Bozovic, M.
    Miler, M.
    Kopcinovic, L. Milevoj
    Unic, A.
    Vrtaric, A.
    Gabaj, N. Nikolac
    CLINICA CHIMICA ACTA, 2024, 558
  • [32] LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
    Gazzi, L.
    Fanelli, F.
    Heiman, F.
    Di Filippo, A.
    Pegoraro, V
    VALUE IN HEALTH, 2018, 21 : S96 - S96
  • [33] METABOLIC CAUSES OF HIGH-RISK LDL CHOLESTEROL (LDL-C)
    VEGA, GL
    GRUNDY, SM
    DENKE, MA
    ARTERIOSCLEROSIS, 1989, 9 (05): : A709 - A710
  • [34] Comparison of Calculated Low-Density Lipoprotein Cholesterol (LDL-C) Values in HIV-Infected and HIV-Uninfected Men Using the Traditional Friedewald and the Novel Martin-Hopkins LDL-C Equations
    Schneider, Edward E.
    Sarkar, Sudipa
    Margolick, Joseph B.
    Martin, Seth S.
    Post, Wendy S.
    Brown, Todd T.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (03) : 176 - 179
  • [35] SIRNA TO PCSK9 IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C: THE ORION 1 TRIAL
    Ray, Kausik K.
    Landmesser, Ulf
    Leiter, Lawrence A.
    Kallend, David
    Wijngaard, Peter L. J.
    Wright, R. Scott
    Kastelein, John J. P.
    ATHEROSCLEROSIS, 2017, 263 : E9 - E10
  • [36] Fixed-dose combination pills reduced SBP and LDL-C in patients with, or at high risk for, cardiovascular disease
    Shekelle, Paul
    ANNALS OF INTERNAL MEDICINE, 2013, 159 (12)
  • [37] Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study
    Mostaza, J. M.
    Garcia-Ortiz, L.
    Tembra, M. A. Suarez
    Calle, P. Talavera
    Garcia, J. Chimeno
    Perez, V. Escolar
    Diaz-Diaz, J. L.
    Manzano-Espinosa, L.
    Catapano, A. L.
    Ray, K. K.
    Moya, G. Diaz
    Montoya, J. Pedro-Botet
    REVISTA CLINICA ESPANOLA, 2025, 225 (02): : 78 - 84
  • [38] Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events
    Balbisi, EA
    MEDICAL SCIENCE MONITOR, 2006, 12 (02): : RA34 - RA39
  • [39] Cardiovascular Risk Patients Reaching LDL-C Target Values is worthwhile
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2021, 30 (03): : 189 - 189
  • [40] Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States
    Unni, Sudhir K.
    Quek, Ruben G. W.
    Biskupiak, Joseph
    Lee, Vinson C.
    Ye, Xiangyang
    Gandra, Shravanthi R.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (01) : 63 - 71
12345